Drug Profile
Buprenorphine - iX Biopharma
Alternative Names: BnoX; Buprenorphine sublingualLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator iX Biopharma
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Pain(In volunteers) in Australia (IV, Injection)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Pain(In volunteers) in Australia (Sublingual, Wafer)
- 23 Feb 2021 Buprenorphine is still in phase I trials for Pain in Australia (Sublingual, Wafer), Australia (IV, Injection) (iX Biopharma pipeline, February 2021)